WuXi Biologics (Cayman) Inc. disclosed on 18 June 2026 that it has made marginal additions to, and substantial repurchases of, its share capital over the past week, according to its latest Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

New share issues • Between 15–18 June 2026 the company allotted a total of 155,000 new ordinary shares upon exercise of options granted under the Pre-IPO Share Option Scheme adopted on 5 January 2016 (amended 10 August 2016). • Issue prices ranged from HKD 1.71 to HKD 2.52 per share. • The new shares represent approximately 0.0037 % of the 4.14 billion shares in issue (excluding treasury shares) before the transactions. • Following the allotments, the company’s issued share capital (excluding treasury shares) rose to 4,142.67 million shares.

Share repurchases pending cancellation • From 27 May to 18 June 2026, WuXi Biologics bought back 31.01 million shares on the Exchange for cancellation, equivalent to 0.75 % of the current issued share base. • Purchases were executed at volume-weighted average prices ranging from HKD 29.46 to HKD 34.45 per share. • The most recent tranche, completed on 18 June 2026, saw 3.26 million shares repurchased at prices between HKD 29.24 and HKD 31.24, for a total consideration of HKD 99.74 million. These shares remain outstanding pending cancellation.

Repurchase mandate utilisation • The repurchases form part of the mandate approved on 10 June 2026 authorising the company to buy back up to 411.99 million shares. • Cumulative buybacks under this mandate now stand at 9.92 million shares, representing 0.24 % of the issued share capital on the mandate date. • In accordance with Hong Kong listing rules, WuXi Biologics is subject to a moratorium on new share issues or treasury-share sales until 18 July 2026.

Capital structure snapshot (as at 18 June 2026, before cancellation of repurchased shares) • Issued shares (excluding treasury shares): 4,142.67 million • Treasury shares: Nil • Shares pending cancellation: 31.01 million

The combination of modest option-related share issuance and ongoing buybacks signals active capital management by WuXi Biologics ahead of the formal cancellation of repurchased shares.